Literature DB >> 28494972

Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.

Stefania Forner1, David Baglietto-Vargas1, Alessandra C Martini1, Laura Trujillo-Estrada1, Frank M LaFerla2.   

Abstract

Alzheimer's disease (AD) is characterized by memory loss, cognitive decline, and devastating neurodegeneration, not only as a result of the extracellular accumulation of beta-amyloid peptide (Aβ) and intracellular accumulation of tau, but also as a consequence of the dysfunction and loss of synapses. Although significant advances have been made in our understanding of the relationship of the pathological role of Aβ and tau in synapse dysfunction, several questions remain as to how Aβ and tau interdependently cause impairments in synaptic function in AD. Overall, more insight into these questions should enable researchers in this field to develop novel therapeutic targets to mitigate or delay the cognitive deficits associated with this devastating disease.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; beta-amyloid; synaptic impairment; tau

Mesh:

Substances:

Year:  2017        PMID: 28494972     DOI: 10.1016/j.tins.2017.04.002

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  113 in total

Review 1.  Long-Term Plasticity of Neurotransmitter Release: Emerging Mechanisms and Contributions to Brain Function and Disease.

Authors:  Hannah R Monday; Thomas J Younts; Pablo E Castillo
Journal:  Annu Rev Neurosci       Date:  2018-04-25       Impact factor: 12.449

2.  Neuronal Network Excitability in Alzheimer's Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau.

Authors:  Syed Faraz Kazim; Joon Ho Seo; Riccardo Bianchi; Chloe S Larson; Abhijeet Sharma; Robert K S Wong; Kirill Y Gorbachev; Ana C Pereira
Journal:  eNeuro       Date:  2021-04-23

Review 3.  Type 2 Diabetes Mellitus and Alzheimer's Disease: Overlapping Biologic Mechanisms and Environmental Risk Factors.

Authors:  Kimberly C Paul; Michael Jerrett; Beate Ritz
Journal:  Curr Environ Health Rep       Date:  2018-03

4.  AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy.

Authors:  A Borreca; V Latina; V Corsetti; S Middei; S Piccinin; F Della Valle; R Bussani; M Ammassari-Teule; R Nisticò; P Calissano; G Amadoro
Journal:  Mol Neurobiol       Date:  2018-03-05       Impact factor: 5.590

5.  Disrupted hippocampal growth hormone secretagogue receptor 1α interaction with dopamine receptor D1 plays a role in Alzheimer's disease.

Authors:  Jing Tian; Lan Guo; Shaomei Sui; Christopher Driskill; Aarron Phensy; Qi Wang; Esha Gauba; Jeffrey M Zigman; Russell H Swerdlow; Sven Kroener; Heng Du
Journal:  Sci Transl Med       Date:  2019-08-14       Impact factor: 17.956

6.  PKC and Ras are Involved in M1 Muscarinic Receptor-Mediated Modulation of AMPA Receptor GluA1 Subunit.

Authors:  Mu-Wen Chen; Han Zhu; Cai-Hong Xiong; Jia-Bing Li; Lan-Xue Zhao; Hong-Zhuan Chen; Yu Qiu
Journal:  Cell Mol Neurobiol       Date:  2019-11-13       Impact factor: 5.046

Review 7.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

Review 8.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

9.  Cell death and survival pathways in Alzheimer's disease: an integrative hypothesis testing approach utilizing -omic data sets.

Authors:  Danielle L Brokaw; Ignazio S Piras; Diego Mastroeni; Daniel J Weisenberger; Jennifer Nolz; Elaine Delvaux; Geidy E Serrano; Thomas G Beach; Matthew J Huentelman; Paul D Coleman
Journal:  Neurobiol Aging       Date:  2020-07-03       Impact factor: 4.673

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.